AbbVie, Worcester, MA, USA.
MAbs. 2013 Jul-Aug;5(4):595-607. doi: 10.4161/mabs.25161. Epub 2013 May 31.
Efficient production of large quantities of therapeutic antibodies is becoming a major goal of the pharmaceutical industry. We developed a proprietary expression system using a polyprotein precursor-based approach to antibody expression in mammalian cells. In this approach, the coding regions for heavy and light chains are included within a single open reading frame (sORF) separated by an in-frame intein gene. A single mRNA and subsequent polypeptide are produced upon transient and stable transfection into HEK293 and CHO cells, respectively. Heavy and light chains are separated by the autocatalytic action of the intein and antibody processing proceeds to produce active, secreted antibody. Here, we report advances in sORF technology toward establishment of a viable manufacturing platform for therapeutic antibodies in CHO cells. Increasing expression levels and improving antibody processing by intein and signal peptide selection are discussed.
大量生产治疗性抗体正成为制药行业的主要目标。我们开发了一种专有的表达系统,该系统使用基于多蛋白前体的方法在哺乳动物细胞中表达抗体。在这种方法中,重链和轻链的编码区包含在单个开放阅读框(sORF)中,由框内内含子基因分隔。在瞬时和稳定转染到 HEK293 和 CHO 细胞后,分别产生单个 mRNA 和随后的多肽。重链和轻链通过内含子的自动催化作用分离,并且抗体加工进行以产生活性的、分泌的抗体。在这里,我们报告了 sORF 技术在建立 CHO 细胞中用于治疗性抗体的可行制造平台方面的进展。讨论了通过内含子和信号肽选择提高表达水平和改善抗体加工的问题。